Protagonist Therapeutics (PTGX) – Analyst EPS Change
-
UPDATE: Protagonist Therapeutics (PTGX) PT Raised to $93 at Piper Sandler on PN-943 Increasing Likelihood of Success
-
Nomura/Instinet Reiterates Buy Rating on Protagonist Therapeutics (PTGX), Expects Upside in PTG-300 Results
Back to PTGX Stock Lookup